Longfei Fang

Associate

Spoken Languages

English Mandarin Japanese

Hong Kong

+852 3658 5329

Longfei Fang

Hong Kong

+852 3658 5329

Translations

English Chinese

Longfei Fang joined Goodwin in 2022 as a department attorney in the firm’s Technology and Life Sciences groups.

Longfei represents biotechnology and pharmaceutical companies in connection with mergers and acquisitions, technology-based transactions, licensing and strategic partnerships as well as financing transactions.

Experience

Longfei’s experience includes representing:

Innovent in a strategic collaboration with Eli Lilly to develop and commercialize programs worldwide outside Greater China
Kelun-Biotech in a strategic partnership with Crescent Biopharma to develop and commercialize SKB105 and CR-001
Leads Biolabs in its exclusive license agreement with Dianthus Therapeutics for LBL-047
TransThera in its royalty-bearing patent assignment and research collaboration agreement with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors
Syneron in its strategic collaboration with AstraZeneca
Vincentage in its license agreement with Corxel Pharmaceuticals for a small molecule glucagon-like peptide-1 receptor agonist
Duality in its exclusive option agreement with GSK for an ADC asset
VelaVigo in its exclusive option agreement with Avenzo for an Nectin4/TROP2 bispecific ADC
Leads Biolabs in an exclusive option and license agreement with a Oblenio Bio, a NewCo formed by Aditum Bio for a CD19xBCMAxCD3 tri-specific T-cell engager antibody for autoimmune diseases
Chengdu Baiyu in an exclusive license agreement with Novartis
Argo biopharma in two exclusive license and collaboration agreements with Novartis for cardiovascular assets
Seagen in an exclusive worldwide license agreement for an ADC asset with Nona Biosciences
Wuxi Biologics in a research service agreement with BioNTech SE to discover two targets of preclinical investigational monoclonal antibodies
Biotheus Inc. in a strategic research collaboration, option and worldwide license agreement with BioNTech SE
C4 Therapeutics in its Licensing Agreement with Betta Pharmaceuticals
Duality Biologics in exclusive license and collaboration agreements for two ADC assets with BioNTech for upfront totaling $170 million, and milestone payments potentially totaling over $1.5 billion
DualityBio Biologics in its exclusive option, license and collaboration agreement with BeiGene
Luye Pharma Group in its license agreement with BeiGene
Kelun-Biotech in its license and collaboration agreement with Merck & Co, Inc.

Arthrosi Therapeutics in its acquisition by Sobi for $950 million upfront and $550 million in milestones
Curon in acquisition of CN201 by Merck for $700 million upfront plus up to $600 million milestones
Proteologix in its acquisition by Johnson & Johnson for $850 million in cash and additional milestone payment
SEED Therapeutics in its Series A-3 financing
KBP Biosciences in its sale to Novo Nordisk of ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, for up to $1.3 billion
LionRock Capital in its acquisition of Haglöfs AB from ASICS Corporation

Professional Activities

Longfei is a qualified PRC patent agent. He is also a Certified Information Privacy Professional (CIPP/E).

Professional Experience

Prior to joining Goodwin, Longfei was at another leading international law firm, where he focused on representing clients in cross-border patent litigation and intellectual property, M&A, and commercial transactions.

While attending law school, Longfei served as an editor for the Columbia Science and Technology Law Review.

Longfei Fang

Experience

Professional Activities

Professional Experience

Credentials

Education

LLM2022

LLM2019

BE2016

BA2016

Admissions

Bars

Related Content

Goodwin Advised Templewater on the Acquisition of The Women’s Clinic Group

Goodwin Advises Kelun-Biotech in Strategic Partnership with Crescent Biopharma to Develop and Commercialize Novel Oncology Therapeutics

Goodwin Advises Arthrosi Therapeutics in Agreement to be Acquired by Sobi for $950 Million Upfront and $550 Million in Milestones

Goodwin Represents FountainVest in its Investment in SML Group

Goodwin Represents Nanjing Leads Biolabs on Exclusive License Agreement with Dianthus Therapeutics for LBL-047 for Up to $1 Billion

Goodwin Guides Syneron Bio on Strategic Collaboration with AstraZeneca for $75 Million and up to $3.4 Billion in Milestones

Goodwin Represents VelaVigo on $440 Million Second Out-Licensing Deal of a First-in-Class Bi-specific Antibody

Goodwin Advises Kelun Biotech and Harbour BioMed on License Agreement with Windward Bio for an Anti-TSLP Fully Human Antibody for Immunological Diseases for up to $970 Million Upfront and in Milestone Payments

Longfei Fang

Experience

Life Sciences Strategic Partnership & Licensing Transaction

M&A / Financing

Professional Activities

Professional Experience

Credentials

Education

LLM2022

LLM2019

BE2016

BA2016

Admissions

Bars

Related Content

Goodwin Advised Templewater on the Acquisition of The Women’s Clinic Group

Goodwin Advises Kelun-Biotech in Strategic Partnership with Crescent Biopharma to Develop and Commercialize Novel Oncology Therapeutics

Goodwin Advises Arthrosi Therapeutics in Agreement to be Acquired by Sobi for $950 Million Upfront and $550 Million in Milestones

Goodwin Represents FountainVest in its Investment in SML Group

Goodwin Represents Nanjing Leads Biolabs on Exclusive License Agreement with Dianthus Therapeutics for LBL-047 for Up to $1 Billion

Goodwin Guides Syneron Bio on Strategic Collaboration with AstraZeneca for $75 Million and up to $3.4 Billion in Milestones

Goodwin Represents VelaVigo on $440 Million Second Out-Licensing Deal of a First-in-Class Bi-specific Antibody

Goodwin Advises Kelun Biotech and Harbour BioMed on License Agreement with Windward Bio for an Anti-TSLP Fully Human Antibody for Immunological Diseases for up to $970 Million Upfront and in Milestone Payments